Prostate cancer (PCa) patients with bone metastases tend to have significant functional impairment from long-term androgen deprivation therapy (ADT), exacerbated by subsequent treatments such as second-line hormone therapies (abiraterone and enzalutamide), first- and second-line chemotherapy or immunotherapies (Hart et al., 2017). They are at significant risk of falls, fractures and consequent hospitalisation. There is a growing body of evidence to support the effectiveness of exercise in addressing the adverse effects of advanced PCa treatment (Hayes et al., 2019). Despite recommendations for men with bone metastases to participate in supervised exercise, there is often a reticence on the part of clinicians and/or patients due to concerns of fragility fracture or other adverse effects (Hart et al., 2017). These men with significant treatment toxicity and a high disease burden are an important patient group for whom exercise has been demonstrated to improve quality of life (QoL) (Galvão et al., 2018). To inform policy and improve accessibility of exercise for advanced PCa patients, it is important to determine whether such interventions represent value for money.